DLI Lab Directory Search

Immunophenotyping of CD40 Ligand (CD154)- positive T lymphocytes, which reports: CD3+CD8-CD154+, CD3+CD8-CD69+.

CD40L (CD154) expression is assessed on CD3+4+8- cells after PMA/Ionomycin activation. Testing includes assessment of CD40 on B cells.

Evaluation of CD40L Upregulation, also includes assessment of binding to receptor using soluble CD40-muIg.

HIGM Panel Includes: CD3, CD4, CD8, CD154, CD40-Fc, CD19, CD40, CD16, CD56, CD14, CD45 Measures CD40 expression on B cells and CD40L expression on activated CD4 cells. Measures binding of CD40L on activated CD4 cells to recombinant CD40 (CD40-muIg).

Analyzes CD40L expression in whole blood, gating on CD3+/CD8- T cells. Reports qualitative result – absent/present.

Neutrophil Oxidative Burst Assay (DHR). White blood cells are incubated with dihydrorhodamine 123 (DHR) and catalase, then stimulated with Phorbol 12-Myristate 13-Acetate (PMA). Dihydrorhodamine oxidation to rhodamine by the respiratory burst of the cell is measured by Semi-Quantitative Flow Cytometry.

Neutrophil’s Oxidative Burst, which reports: Neutrophil Oxidative Index (MFI DHR+ / MFI DHR-), and % Responding Polymorphonuclear Cells.

Functional CGD screening assay, using DHR123 loaded neutrophils pre and post stimulation with PMA to induce oxidative burst reaction.

Classic dihydrorhodamine (DHR) 123 assay.

Dihydrorhodamine 123 Neutrophil oxidative burst (DHR). Reports stimulation index

Chronic granulomatous disease diagnostic screening assay for oxidative burst using dihydrorhodamine (DHR) 123.

Classic dihydrorhodamine (DHR) 123 assay with PMA stimulation.

Classic dihydrorhodamine (DHR) 123 assay.

NPF Panel Includes: CD45, CD15, CD18 Dihydrorhodamine (DHR) 123 assay. Measures the ability of neutrophils to generate an oxidative burst following stimulation with PMA or fMLP. The expression of CD15 and CD18 on neutrophils is also measured. Screening test for chronic granulomatous disease (CGD) and leucocyte adhesion deficiency type I and type II.

NPF Panel: CD45, CD15, CD18 Dihydrorhodamine (DHR) 123 assay. Measures the ability of neutrophils to generate an oxidative burst following stimulation with PMA or fMLP. The expression of CD15 and CD18 on neutrophils is also measured. Screening test for chronic granulomatous disease (CGD) and leucocyte adhesion deficiency type I and type II.

Neutrophil’s oxidation (DHR) by flow cytometry.

Classic dihydrorhodamine (DHR) 123 assay. Offers NBT assay as back up.

Neutrophil oxidation assay uses dihydrorhodamine (DHR) 123 and PMA. Report includes MFI ratio.

Neutrophil Function, Oxidative Burst. Classic dihydrorhodamine (DHR) 123 assay.

Classic dihydrorhodamine (DHR) 123 assay with PMA stimulation.

Oxidative Burst: Whole blood is stimulated with PMA or buffer alone, Formation of the reactive oxidants during the oxidative burst is monitored by the addition and enzymatic oxidation of a fluorogenic substrate, DHR 123. The level of reactive oxygen radicals is determined by flow cytometry.

DNA Double-strand Break Repair Assessment in Lymphocytes – This test is useful for the diagnosis of monogenic defects associated with defects in DNA repair and associated radiosensitivity (XCIND - X-ray irradiation susceptibility, Cancer predisposition, Immunodeficiency and Neurological Defects), bone marrow failure syndromes, short telomere syndromes, excessive toxicity to chemotherapy and radiation. This test can be used to develop appropriate conditioning regimen selection in patients with these defects who require hematopoietic cell transplantation. DDRFL primarily assesses for the presence of DNA double-strand breaks in each lymphocyte subset (T, B and NK cells) and the associated repair mechanism (NHEJ, non-homologous end-joining), and excessive cell death following irradiation of lymphocytes. Markers used in this assay include CD45, CD3, CD19, CD335 (NKp46), pATM, pSMC1 and gamma H2AX. The test measures viability in the sample at baseline (Day 0), 1h and 24h radiosensitivity, and 24h assessment of cell death and apoptosis after irradiation.

Assay tests TLR4 function by assessing the ability of monocytes to produce TNF-α in response to LPS and MDP (to test XIAP function) stimulation. Defective response can be seen in IRAK4/MyD88 deficiency and XIAP deficiency.

Measurement of STAT5 phosphorylation following GMCSF stimulation. (GMCSF autoantibody testing also available.)

Measures phosphorylation/dephosphorylation STAT5 (IL2, IL3, IL15, and GMCSF-induced) by flow cytometry.

ELISA measurement of GM-CSF autoantibodies, and reflex testing of P-STAT5 inhibition for positive samples.

Assay measures the ability of IL-10 to suppress IL-6 synthesis from monocytes in response to LPS stimulation, which is dependent on the functional integrity of the IL10 receptors and STAT3. Detects functional defects due to IL10R deficiency or autosomal dominant mutations in STAT3 leading to the Hyper-IgE Syndrome.

Fas-mediated apoptosis assay. T cells are treated with APO-1-3 and protein A to induce cell death, following a 11 day culture, using Concanavalin A and IL-2. The % cell loss is calculated and reported.

MSMD Panel: CD3, CD4, CD8, CD45RA, CD45RO, CD16, CD56, CD19, CD14, CD45, HLA-DR, CD212, CD119, IL-12, pSTAT1, pSTAT4 Measures expression of INF-R1 and IL12-1 receptors (CD119 and CD212), INF induced STAT1-phosphorylation and IL-12-induced STAT4-phosphorylation as well as IL12 production. Screening assay to detect genetic defects involving CD119, CD212, STAT1 and IL12 leading to an increased susceptibility to mycobacterial disease.

Two tests can be ordered: 1 - IL-12/gIFN cytokines secretion (ELISA). 2 - Measures of phosphorylation/dephosphorylation of STAT1 in response to gIFN by flow cytometry.

Phenotypic analysis of IFNγR1 and IL-12 (beta chain) receptors.

Functional assay in which peripheral blood T cells are stimulated with IL-6 to induce phosphorylation of STAT3 or alternatively, stimulation with IL-2 to induce phosphorylation of STAT5.

Analyzes phosphorylation of STAT5 in peripheral blood lymphocytes following stimulation of peripheral blood mononuclear cells with IL-2.

Measures phosphorylation/dephosphorylation of STAT3 (IL10 and IL6-induced) and STAT5 (IL2, IL3, IL15, and GMCSF-induced) by flow cytometry.

Measures % of Th17 cells in the CD3+4+ subset following stimulation with PMA/Ionomycin.

Quantifies CD4+ CCR6+ T cells in comparison to an age-based range, and measures IL-17 production following stimulation with Phorbol 12-Myristate 13 Acetate (PMA) and Ionomycin which allows quantitation of TH17 cells.

THIL17 Panel Includes: CD3, CD4, CD8, CD19, CD16, CD56, CD14, CD45, IFN-γ, IL-17 Assay measures T cell-specific IFN-γ and IL-17 production by PMA/Ionomycin stimulated PBMCs. Deficient expression is associated with hyper IgE syndrome (HIES)/Job’s Syndrome and also severe eczema.

Measures IL-17 production following stimulation with Phorbol 12-Myristate 13 Acetate (PMA) and Ionomycin in CD4 T cells.

Offers % of TH1 (IFNg) and TH17 (IL-17) CD4 T cells in PBMC following PMA/Ionomycin stimulation.

Toll-Like Receptor Function. Results for TNF alpha, IL-1 beta, IL-6, and CXCL10 are reported as pg/mL. Method: Cell Culture/Quantitative Multiplex Bead Assay.

Assay tests TLR4 function by assessing the ability of monocytes to produce TNF-α in response to LPS and MDP (to test XIAP function) stimulation.

Assay tests TLR4 function by assessing the ability of monocytes to produce TNF-α in response to LPS and MDP (to test XIAP function) stimulation. Defective response can be seen in IRAK4/MyD88 deficiency and XIAP deficiency.

TLR 2-4 activation: CD62L shedding assay (only local samples for technical reasons) and IL-6 and TNF secretion (ELISA).

TLR 3 activation in NK cells (CD69 and CD25 expression) by flow cytometry.

Whole blood stimulation with multiple ligands, Lipoteichoic Acid (TLR2), Zymosan (TLR2/6), LPS (TLR4), Flagellin (TLR5), and Bacterial DNA (TLR9) followed by TNF-alpha analysis.